Literature DB >> 6250935

Central inhibition of basal pancreatic and gastric secretions by beta-endorphin in rats.

C Rozé, M Dubrasquet, J Chariot, C Vaille.   

Abstract

The effects of intracerebroventricular injections of synthetic ovine beta-endorphin were tested in conscious rats with gastric and pancreatic fistulas. In the range of 0.8 to 25 microgram injected in the third ventricle of the brain, basal gastric and pancreatic secretions were strongly inhibited in a dose-dependent manner. Pancreatic volume, bicarbonate output, and total protein output were similarly inhibited, while the bicarbonate concentration was only slightly changed. Similar effects were noted after the administration of morphine. In the present model system, morphine was 20-30 times less active than beta-endorphin on a molar basis. Beta-Endorphin inhibition of pancreatic secretion was reversed by naloxone, suggesting that opiate receptors are involved in this phenomenon. Gastric acid secretion participated in the pancreatic effects of beta-endorphin to only a slight extent, since pancreatic inhibition by the endorphin was decreased only slightly in rats with gastic fistula in which gastric juice was diverted and did not reach the duodenum. The comparison of intravenous and intraventricular injections of beta-endorphin and morphine suggested that the observed inhibitions originated in the central nervous system. No effects were detected after the administration of alpha-endorphin, Met-enkephalin or Leu-enkephalin, although pancreatic secretion was measurably inhibited by long-acting synthetic enkephalin analogues.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6250935

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

1.  Effect of endorphins on amylase secretion from rat pancreas in vivo and in vitro.

Authors:  M Singh
Journal:  Dig Dis Sci       Date:  1985-03       Impact factor: 3.199

2.  Stimulation of central alpha-2 adrenoceptors inhibits gastric secretion in rats by releasing vasopressin.

Authors:  J Puurunen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

Review 3.  Neurobiologic and psychobiologic mechanisms in gastric function and ulceration.

Authors:  H Weiner; D Novin; C V Grijalva; Y Taché; T Garrick
Journal:  West J Med       Date:  1985-08

4.  Role of putative neurotransmitters in the central gastric antisecretory effect of prostaglandin E2 in rats.

Authors:  J Puurunen
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

5.  Growth-hormone releasing factor does not antagonize somatostatin effects on pancreatic and gastric secretions.

Authors:  M Chovet; M Dubrasquet; J Chariot; C Rozé
Journal:  Experientia       Date:  1985-11-15

6.  Inhibition of postprandial pancreatic and biliary secretion by loperamide in patients with short bowel syndrome.

Authors:  M Remington; C R Fleming; J R Malagelada
Journal:  Gut       Date:  1982-02       Impact factor: 23.059

7.  Stimulation of exocrine pancreatic secretion by met-enkephalin.

Authors:  L Gullo; P Priori; F Baldoni; G Mattioli
Journal:  Gut       Date:  1986-12       Impact factor: 23.059

8.  Corticotropin-releasing factor. Mechanisms to inhibit gastric acid secretion in conscious dogs.

Authors:  H J Lenz; S E Hester; M R Brown
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

9.  Influence of dopamine receptor agonists on gastric acid secretion induced by intraventricular administration of thyrotropin-releasing hormone in the perfused stomach of anaesthetized rats.

Authors:  M Maeda-Hagiwara; K Watanabe
Journal:  Br J Pharmacol       Date:  1983-05       Impact factor: 8.739

10.  Studies of the role of opioids in control of human pancreatic secretion.

Authors:  C P Dooley; C Saad; J E Valenzuela
Journal:  Dig Dis Sci       Date:  1988-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.